Further experimentation will be required using models of acquired CHK1i resistance to determine whether this is a common feature of CHK1i resistance or a consequence of disrupted NF-κB signalling in the context of the Eμ-Myc lymphoma model. The gene discussed is NFKB1; the disease is lymphoma.